Flat dose-response curves for efficacy: What do they mean to the clinician?

Journal of Psychiatric Practice

Volumn 14, Issue 4, 2008, Pages 232-236

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; CYCLOHEXANOL DERIVATIVE; DESVENLAFAXINE; NEUROTRANSMITTER UPTAKE INHIBITOR; O-DESMETHYLVENLAFAXINE; UNCLASSIFIED DRUG;

DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUSTRY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HUMAN; NAUSEA; REVIEW; UNSPECIFIED SIDE EFFECT; ARTICLE; DRUG ADMINISTRATION; HEALTH PERSONNEL ATTITUDE; MAJOR DEPRESSION; PHYSICIAN; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

ATTITUDE OF HEALTH PERSONNEL; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; PAROXETINE; PHYSICIANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERTRALINE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 58149180773     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000327313.81281.fd     Document Type: Review

References (22)

1. Pristiq package insert. Philadelphia, PA:Wyeth Pharmaceuticals, April, 2008 (available at www.wyeth.com/content/showlabeling .asp?id=497).
2. Liebowitz MR,Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007;68:1663-72.
3. Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-47.
4. DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88.
5. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
6. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression trial report. Biol Psychiatry 2006;59:493-501.
7. Bandelow B, Brunner E, Beinroth D, et al. Application of a new statistical approach to evaluate a clinical trial with panic disorder patients. Eur Arch Psychiatry Clin Neurosci 1999;249:21-7.
8. Matsuyama Y, Ohashi Y. Mixed models for bivariate response repeated measures data using Gibbs sampling. Stat Med 1997;16:1587-601.
9. Tibaldi FS, Verbeke G, Molenberghs G, et al. Conditional mixed models with crossed random effects. Br J Math Stat Psychol 2007;60(Pt 2):351-65.
10. French B, Heagerty PJ. Marginal mark regression analysis of recurrent marked point process data. Biometrics 2008 Jun 20. [Epub ahead of print].
11. Frost C, Kenward MG, Fox NC. Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency? Stat Med. 2008 May 16. [Epub ahead of print].
12. Schildcrout JS, Heagerty PJ. On outcome-dependent sampling designs for longitudinal binary response data with time-varying covariates. Biostatistics 2008 Mar 27. [Epub ahead of print].
13. Simpson HB, Petkova E, Cheng J, et al. Statistical choices can affect inferences about treatment efficacy: A case study from obsessive-compulsive disorder research. J Psychiatr Res 2008;42:631-8.
14. Wu L, Hu XJ, Wu H. Joint inference for nonlinear mixed-effects models and time to event at the presence of missing data. Biostatistics 2008;9:308-20.
15. Wernicke JF, Dunlop SR, Dornseif BE, et al. Low dose fluoxetine therapy for depression. Psychopharmacol Bull 1988;24:183-8.
16. Wernicke JF, Dunlop SR, Dornseif BE, et al. Fixed dose fluoxetine therapy for depression. Psychopharmacol Bull 1987;23: 164-8.
17. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992;53(suppl 2):21-6.
18. Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995;38:592-602.
19. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors, first edition. Caddo, OK: Professional Communications; 1996:50.
20. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-35.
21. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.Am J Psychiatry 2001;158:1843-9.
22. Preskorn SH. Practical application of therapeutic drug monitoring: A tale of two patients. J Psychiatr Pract 2008;14: (in press) (also available at www.preskorn.com /columns/9905.html).